Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status

Figure 2

Nimotuzumab and rapamycin combination treatment enhanced therapeutic efficacy in Asian Glioma cell lines. (A) Western blot analysis was done to check the EGFR expression status in G5T/VGH, GBM8401 and GBM8901 Asian glioma cell lines with respective (+) controls. These cell lines were treated with TMZ (500 μM), rapamycin (0.1 mM) or Nimotuzumab (0.013 mM) as single treatments or combination of rapamycin and Nimotuzumab for 24 h and percentage of cell viabilities of G5T/VGH (B), GBM8401 (C) and GBM8901 (D) were determined. Data are presented as mean ± SEM. Combination groups were compared to each single drug treatments in individual cell line *p < 0.05, ***p < 0.001.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us